Ignite Creation Date:
2025-12-25 @ 3:21 AM
Ignite Modification Date:
2026-05-31 @ 12:17 AM
Study NCT ID:
NCT00144105
Status:
TERMINATED
Last Update Posted:
2013-11-01
First Post:
2005-09-02
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Randomised Trial to Evaluate the Antiviral Efficacy and Safety of Treatment With 500 mg Tipranavir (TPV) Plus 100 mg or 200 mg Ritonavir (RTV) p.o. BID in Comparison to 400 mg Lopinavir (LPV) Plus 100 mg RTV p.o. BID in Combination With Standard Background Regimen in ARV Therapy naïve Patients.
Sponsor:
Boehringer Ingelheim
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
1182.33
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
None
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None